Targeting Oncogenic Pathways: Advances in KRAS, CDK, EGFR, and PROTAC-Based Therapies

被引：0
|
作者：
Kargbo, Robert B. [1 ]
机构：
[1] Usona Inst, Fitchburg, WI 53711 USA
来源：
ACS MEDICINAL CHEMISTRY LETTERS | 2025年
关键词：
D O I：
10.1021/acsmedchemlett.5c00111
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Recent advancements in cancer therapy focus on targeting critical mutations and regulatory pathways, particularly KRAS mutations and cyclin-dependent kinases (CDKs), which drive cancer progression. This Patent Highlight showcases the development of novel small-molecule inhibitors for KRAS and CDKs, highlighting their mechanisms of action, critical findings from preclinical studies, and the potential for improving therapeutic outcomes in cancers such as nonsmall cell lung cancer (NSCLC), colorectal, and pancreatic cancers.
引用
收藏
页数：3
相关论文
共 23 条
  • [1] Advancements in PROTAC-based therapies for neurodegenerative diseases
    Kong, Deyuan
    Meng, Liying
    Lin, Pengfei
    Wu, Guanzhao
    FUTURE MEDICINAL CHEMISTRY, 2025, 17 (05) : 591 - 605
  • [2] Recent Advances in PROTAC-Based Antiviral Strategies
    Ahmad, Haleema
    Zia, Bushra
    Husain, Hashir
    Husain, Afzal
    VACCINES, 2023, 11 (02)
  • [3] Innovative Cancer Therapies: Targeting Oncogenic Pathways through Placental Immunology, PROTAC Technology, and Kinase Degradation
    Kargbo, Robert B.
    ACS MEDICINAL CHEMISTRY LETTERS, 2024, 15 (12): : 2077 - 2079
  • [4] Development of a PROTAC-Based Targeting Strategy Provides a Mechanistically Unique Mode of Anti-Cytomegalovirus Activity
    Hahn, Friedrich
    Hamilton, Stuart T.
    Wangen, Christina
    Wild, Markus
    Kicuntod, Jintawee
    Brueckner, Nadine
    Follett, Jasmine E. L.
    Herrmann, Lars
    Kheimar, Ahmed
    Kaufer, Benedikt B.
    Rawlinson, William D.
    Tsogoeva, Svetlana B.
    Marschall, Manfred
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (23)
  • [5] Targeting Venetoclax Resistant CLL Using a Protac-Based BCL-2/BCL-XL Degrader
    Rohena, Daisy Diaz
    Slawin, Bailey
    Ravikrishnan, Janani
    Liu, Chaomei
    Hu, Wanyi
    Zhang, Peiyi
    Thompson, Philip A.
    Wierda, William G.
    Jain, Nitin
    Zheng, Guangrong
    Zhou, Daohong
    Woyach, Jennifer A.
    Sampath, Deepa
    BLOOD, 2022, 140
  • [6] Enriched Signalling Pathways in Venetoclax-Relapsed Chronic Lymphocytic Leukemia (CLL) Cells and Targeting Using a Protac-Based Bcl-2/Bcl-Xl Degrader
    Rohena, Daisy Diaz
    Cuesta, Arnau Peris
    Slawin, Bailey
    Ravikrishnan, Janani
    Liu, Chaomei
    Williams, Charmelle
    Hu, Wanyi
    Zhang, Peiyi
    Thompson, Philip
    Wierda, William G.
    Jain, Nitin
    Shukla, Sachet
    Zheng, Guangrong
    Zhou, Daohong
    Woyach, Jennifer A.
    Sampath, Deepa
    BLOOD, 2023, 142
  • [7] Multidimensional Screening Platform for Simultaneously Targeting Oncogenic KRAS and Hypoxia-Inducible Factors Pathways in Colorectal Cancer
    Bousquet, Michelle S.
    Ma, Jia Jia
    Ratnayake, Ranjala
    Havre, Pamela A.
    Yao, Jin
    Dang, Nam H.
    Paul, Valerie J.
    Carney, Thomas J.
    Dang, Long H.
    Luesch, Hendrik
    ACS CHEMICAL BIOLOGY, 2016, 11 (05) : 1322 - 1331
  • [8] SOMATIC KRAS MUTATIONS AND RESISTANCE TO EGFR-TARGETED THERAPIES: IS KRAS READY TO INCLUDE AS A REFLEX TEST WITH EGFR IN NSCLC? AN EVIDENCE SYNTHESIS BASED APPROACH
    Murray, S.
    Siannis, F.
    Bafaloukos, D.
    Kosmidis, P.
    Linardou, H.
    ANNALS OF ONCOLOGY, 2012, 23 : 85 - 86
  • [9] Targeting oncogenic KRAS in non-small cell lung cancer with EGFR aptamer-conjugated multifunctional RNA nanoparticles
    Yang, Linlin
    Li, Zhefeng
    Binzel, Daniel W.
    Guo, Peixuan
    Williams, Terence M.
    MOLECULAR THERAPY NUCLEIC ACIDS, 2023, 33 : 559 - 571
  • [10] Recent advances in the development of inhibitors targeting KRAS-G12C and its related pathways
    Zhao, Dongqiang
    Liu, Yu
    Yi, Fengchao
    Zhao, Xia
    Lu, Kui
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 259
123